<DOC>
	<DOCNO>NCT02598583</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability efficacy multiple IV dose ALXN1210 administer patient PNH</brief_summary>
	<brief_title>An Open-Label , Intrapatient , Dose-Escalation Study Evaluate Safety , Tolerability , Efficacy , Pharmacokinetics , Pharmacodynamics ALXN1210 Administered Intravenously Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>1 . Male female â‰¥ 18 year age 2 . PNH diagnosis confirm documented highsensitivity flow cytometry 3 . Documented meningococcal vaccination 3 year prior dose 4 . Female patient childbearing potential must use highly effective contraception start screen continue least 8 month last dose ALXN1210 . 5 . Willing able give write informed consent comply study visit schedule 1 . Treatment complement inhibitor time 2 . Females pregnant , breastfeed positive pregnancy test screen Day 1 3 . Participation interventional clinical study within 30 day initiation dose Day 1 , use experimental therapy within 30 day prior dose Day 1 , within 5 half life product , whichever great 4 . History allergy excipients ALXN1210 know allergy Chinese hamster ovary ( CHO ) cell proteins 5 . Inability comply study requirement 6 . History clinically significant cardiac , hepatic , immunologic , pulmonary , rheumatoid disease , Investigator 's judgment , would preclude participation 7 . Other unspecified reason , opinion Investigator Sponsor , make patient unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>PNH</keyword>
	<keyword>complement inhibitor</keyword>
</DOC>